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Summary: The majority of the research shows that when the HPV 
vaccination is recommended by the PCP, as opposed to ancillary staff, 
there is an increase in vaccination rates. The research also shows a 
correlation between decreased cancer rates with vaccination 
administration.
• According to the CDC, about 1 in 4 people 
currently have the HPV virus. 1
• HPV (human papilloma virus) causes 
different types of cancers in men and 
women.1
• Including: cervical carcinomas and 
squamos cell carcinomas of the vagina, 
vulva, penis, anus, rectum, and 
oropharynx.1
• The HPV vaccine is highly efficacious in 
preventing several HPV-related cancers – if 
given prior to HPV exposure.1
• “HPV is thought to be responsible for more 
than 90% of anal and cervical cancers, 
about 70% of vaginal and vulvar cancers, 
and more than 60% of penile cancers.”1
• Worldwide, HPV is the most common 
sexually transmitted disease. 
Needs Assessment
• National Coverage is at 49% 1 
• Texas 57.8% 1
• City of Houston -73%, only city in Texas 1
• Healthy People 2020  target is 80%.5 
• “Fewer adolescents in rural areas, 
compared with adolescents in urban areas, 
are getting the HPV and meningococcal 
conjugate vaccines” 1.
PICOT Question
In children 11 to 12 years of age, how do HPV 
vaccination completion rates differ between  
provider recommendation to vaccinate vs 
ancillary staff recommendation to vaccinate, 
over a 6-month period?
Implementation
Evaluation Plan
Literature Review
EBP Guidelines
Theoretical Framework
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• Current research indicates the PCP should initiate all conversations 
about HPV vaccinations.2,5
• A presumptive recommendation and case in favor of the vaccination 
should be made by the PCP.2,5
• CDC Recommends best practice as follows:
• Given as routine vaccinations to males and females 11-12 years of 
age, but can start as early as 9 years.1 
Successful Implementation:
• Evaluation: 
• Is there an increase in the rate of HPV 
vaccinations among 11-12 year old’s
• Is there an increase in completion of 2 
dose vaccine schedule?
• Comparison of chart audits before 
implementation versus chart audits 6-
months after implementation of provider-
led recommendation for HPV vaccine
E-Evidence:
• Provide 1 page fact sheet with statistics on 
preventable cancers.
C-Context:
• Obtain leadership support- emphasize 
Healthy People 2020 goals
• Obtain provider support by addressing 
barriers
• Obtain staff support by empowering staff 
to communicate effectively
F-Facilitation:
• Educate using in-service regarding HPV 
vaccine with open forum for employees to 
voice their concerns.
• Education focusing on cancer prevention.
• Review EBP guidelines: provider 
recommendations/presumptive 
recommendation.
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Inclusion 
Criteria
• Duplicate studies
• Adolescents/adults over 26 years
• Adolescents not in the U.S. 
• Studies not done in English
• Not within 2013-2018
Exclusion 
Criteria
Age: 9-14 
• Two doses total for this age range
• Dosages 6 to 12 months apart
Age: 15-26 
• Three doses total for this age range
• First two, 6 to 12 months apart
• 3rd dose, 6 months after 2nd dose
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Successful 
Implementation
Evidence
ContextFacilitation
Promoting Action on Research Implementation 
in Health Services (PARiHS) Framework3,4
SI-Successful Implementation: is a 
“function of the relation between the nature 
of the evidence, the context in which the 
proposed change is to be implemented and 
the mechanisms by which the change is 
facilitated”.2
